FDA 2026 COMPOUNDING REVIEW

Semax

Jurisdiction specific clinical history is frequently mistaken for UK or US regulatory acceptance.

Record version 1.0Last verified 5 September 2026Evidence grade CRegulatory surveillance cohort

FDA STATUS

Not FDA approved; advisory review is not drug approval

MHRA / UK LICENCE

No UK marketing authorisation identified

NICE STATUS

No NICE recommendation identified

NHS ACCESS

No routine NHS access

PRIVATE LAWFUL USE CONTEXT

Foreign or research use is not UK marketing authorisation

EVIDENCE MATURITY

International and limited evidence is not equivalent to US or UK authorisation

DEVELOPMENT PHASE

Regulatory surveillance cohort

MARKET EXPOSURE

High nootropic market

PROFESSIONAL RELEVANCE

Map international evidence and product status without importing foreign claims into UK authorisation language.

Product, formulation and indication

No authorised product is represented for this investigational or surveillance record. Product level data will be added only when a sourceable regulated product exists.

Status history

5 September 2026

Production baseline verification recorded.

FDA PCAC reviewed a 503A bulk substance nomination in July 2026

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.